Norstella

Norstella

Norstella operates as a holding company for a set of pharmaceutical solutions providers, each historically independent: Evaluate (pharma intelligence), MMIT (market access data), Citeline (trial intelligence), Panalgo (real-world analytics), and Entact (payer data assets). The group formed from the 2021 merger of MMIT and Evaluate, backed by private equity, though the precise founding date and ownership structure are not publicly detailed by the firm. The strategy centers on integrating these brands onto a common AI platform called LinQ, which combines real-world data, predictive analytics, and patient-centric models. Norstella's offerings span forecasting, clinical trial design, market access strategy, and patient activation — covering the full drug development life cycle from pipeline to patient. The firm claims over 20,000 clinical trials start each year and more than half of new FDA approvals are first-in-class, positioning its data tools to manage risk and optimize R&D allocation. Norstella employs no publicly disclosed total professional headcount. The firm maintains offices across 10 cities globally, including Livingston (NJ), New York, London, Manchester, Amsterdam, Tokyo, Bangalore, Gurgaon, Noida, and Shanghai. In March 2026, Recursion Pharmaceuticals expanded a strategic partnership with Citeline (one of Norstella's brands) to advance its AI-enabled clinical technology platform (per Norstella, March 2026). No philanthropic arm or adjacent investment vehicle is disclosed. Norstella distinguishes itself by operating as a vertically integrated data and analytics group that competes with large health-tech vendors like IQVIA, not as a traditional asset manager or family office. The firm's structure mirrors a platform roll-up — bundling disjointed market-access, trial-intelligence, and real-world-data assets — and it is privately owned, though the ultimate sponsor or ownership group is not publicly named.